Gastric carcinoma in china: Current status and future perspectives (review)

Oncology Letters

Volumn 1, Issue 3, 2010, Pages 407-412

  Zhu, Xiaodong ^a   Li, Jin ^a  

^a FUDAN UNIVERSITY   (China)

Author keywords

Antineoplastic combined chemotherapy protocols; Clinical protocols; Stomach neoplasms; Therapeutics

Indexed keywords

ANTHRACENE; CAPECITABINE; EPIRUBICIN; FLUOROURACIL; NAVELBINE; NITROSOUREA; OXALIPLATIN; SEMUSTINE; TAXANE DERIVATIVE;

ARTICLE; CANCER ADJUVANT THERAPY; CANCER STAGING; CANCER SURGERY; CHINA; HUMAN; STOMACH CANCER; STOMACH CARCINOMA;

EID: 77955739215     PISSN: 17921074     EISSN: 17921082     Source Type: Journal    
DOI: 10.3892/ol_00000071     Document Type: Article

References (50)

1. Yang L: Incidence and mortality of gastric cancer in China. World J Gastroenterol 12: 17-20, 2006.
2. Sun XD, Mu R, Zhou YS, et al: Analysis of mortality rate of stomach cancer and its trend in twenty years in China. Zhonghua Zhong Liu Za Zhi 26: 4-9, 2004.
3. Japanese Research Society for Gastric Cancer: The General Rules for the Gastric Cancer Study in Surgery and Pathology. 12th edition. Kanahara Shuppan, Tokyo, 1993.
4. Roder JD, Böttcher K, Busch R, et al: Classification of regional lymph node metastasis from gastric carcinoma. German Gastric Cancer Study Group. Cancer 82: 621-631, 1998.
5. Weber WA and Ott K: Imaging of esophageal and gastric cancer. Semin Oncol 31: 530-541, 2004.
6. Bozzetti F, Marubini E, Bonfanti G, et al: Subtotal versus total gastrectomy for gastric cancer: five-year survival rates in a multicenter randomized Italian trial. Italian Gastrointestinal Tumor Study Group. Ann Surg 230: 170-178, 1999.
7. Hartgrink HH, van de Velde CJ, Putter H, et al: Extended lymph node dissection for gastric cancer: who may benefit? Final results of the randomized Dutch Gastric Cancer Group trial. J Clin Oncol 22: 2069-2077, 2004.
8. Cuschieri A, Weeden S, Fielding J, et al: Patient survival after D1 and D2 resections for gastric cancer: long-term results of the MRCrandomized surgical trial. Surgical Co-operative Group. Br J Cancer 79: 1522-1530, 1999.
9. Jansen EP, Boot H, Verheij M and van de Velde CJ: Optimal locoregional treatment in gastric cancer. J Clin Oncol 23: 4509-4517, 2005.
10. Van de Velde CJ and Peeters KC: The gastric cancer treatment controversy. J Clin Oncol 21: 2234-2236, 2003.
11. Degiuli M, Sasako M, Ponti A and Calvo F: Survival results of a multicentre phase II study to evaluate D2 gastrectomy for gastric cancer. Br J Cancer 90: 1727-1732, 2004.
12. Kodama I, Kofuji K, Yano S, et al: Lymph node metastasis and lymphadenectomy for carcinoma in the gastric cardia: clinical experience. Int Surg 83: 205-209, 1998.
13. Yonemura Y, Katayama K, Kamata T, et al: Surgical treatment of advanced gastric cancer with metastasis in para-aortic lymph node. Int Surg 76: 222-225, 1991.
14. Qie XD, Chen B, Wang J, et al: Comparison for treatment experience of gastric cancer between China Medical University and University of Tokyo-a report of 2438 cases. Med J Liaoning 16: 238-240, 2002.
15. Wu CW, Hsiung CA, Lo SS, et al: Nodal dissection for patients with gastric cancer: a randomised controlled trial. Lancet Oncol 7: 309-315, 2006.
16. Sano T, Sasako M, Yamamoto S, et al: Gastric cancer surgery: morbidity and mortality results from a prospective randomized controlled trial comparing D2 and extended para-aortic lymphadenectomy-Japan Clinical Oncology Group study 9501. J Clin Oncol 22: 2767-2773, 2004.
17. Chen L, Zhu ZG, Yan M, et al: Clinical values of surgical management for stage IV gastric cancer. J Shanghai Jiaotong University (Medical Science) 27: 569-572, 2007.
18. Cunningham D, Allum WH, Stenning SP, et al: Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. NEngl J Med 355: 11-20, 2006.
19. Fang Y, Wang YJ, Li F and Li J: Oxaliplatin in combination with calcium folinate and fluorouracil as neoadjuvant chemotherapy in the treatment of advanced gastric cancer. Zhonghua Wei Chang Wai Ke Za Zhi 9: 510-512, 2006.
20. Yang J and Wang ZG: The combination of docetaxel, cisplatin, fluorouracil and leucovorin (CF) as neoadjuvant chemotherapy for the treatment of non-resectable advanced gastric cancer. China Oncol 16: 346-350, 2006.
21. Zhang ZX, Gu XZ, Yin WB, Huang GJ, Zhang DW and Zhang RG: Randomized clinical trial on the combination of preoperative irradiation and surgery in the treatment of adenocarcinoma of the gastric cardia (AGC)-report on 370 patients. Int J Radiat Oncol Biol Phys 42: 929-934, 1998.
22. The Gastrointestinal Tumor Study Group: Controlled trial of adjuvant chemotherapy following curative resection for gastric cancer. Cancer 49: 1116-1122, 1982.
23. Higgins GA, Amadeo JH, Smith DE, Humphrey EW and Keehn RJ: Efficacy of prolonged intermittent therapy with combined 5-FU and methyl-CCNU following resection for gastric carcinoma. A Veterans Administration Surgical Oncology Group report. Cancer 52: 1105-1112, 1983.
24. Hermans J, Bonenkamp JJ, Boon MC, et al: Adjuvant therapy after curative resection for gastric cancer: meta-analysis of randomized trials. J Clin Oncol 11: 1441-1447, 1993.
25. Earle CC and Maroun JA: Adjuvant chemotherapy after curative resection for gastric cancer in non-Asian patients: revisiting a meta-analysis of randomised trials. Eur J Cancer 35: 1059-1064, 1999.
26. Janunger KG, Hafström L and Glimelius B: Chemotherapy in gastric cancer: a review and updated meta-analysis. Eur J Surg 168: 597-608, 2002.
27. Mari E, Floriani I, Tinazzi A, et al: Efficacy of adjuvant chemotherapy after curative resection for gastric cancer: a meta-analysis of published randomised trials. A study of the GISCAD (Gruppo Italiano per lo Studio dei Carcinomi dell'Apparato Digerente). Ann Oncol 11: 837-843, 2000.
28. Sakuramoto S, Sasako M, Yamaguchi T, et al: Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine. N Engl J Med 357: 1810-1820, 2007.
29. Macdonald JS, Smalley SR, Benedetti J, et al: Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction. N Engl J Med 345: 725-730, 2001.
30. Lim DH, Kim DY, Kang MK, et al: Patterns of failure in gastric carcinoma after D2 gastrectomy and chemoradiotherapy: a radiation oncologist's view. Br J Cancer 91: 11-17, 2004.
31. Kang Y, Kang WK, Shin DB, et al: Randomized phase III trial of capecitabine/cisplatin (XP) vs. continuous infusion of 5-FU/cisplatin (FP) as first-line therapy in patients (pts) with advanced gastric cancer (AGC): efficacy and safety results. Proc Am Soc Clin Oncol 24: abs. LBA4018, 2006.
32. Van Cutsem E, Moiseyenko VM, Tjulandin S, et al; V325 Study Group: Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 Study Group. J Clin Oncol 24: 4991-4997, 2006.
33. Cunningham D, Starling N, Rao S, et al; Upper Gastrointestinal Clinical Studies Group of the National Cancer Research Institute of the United Kingdom: Capecitabine and oxaliplatin for advanced esophagogastric cancer. NEngl J Med 358: 36-46, 2008.
34. Jin ML, Chen Q, Cheng FQ, et al: Oxaliplatin (OXA) in combination with LV5FU2 in Chinese patients with advanced gastric cancer (AGC). Proc Am Soc Clin Oncol 21: abs. 558, 2002.
35. Zhu X, Leaw J, Gu W, et al: Phase II clinical trial of advanced and metastatic gastric cancer based on continuous infusion of 5-fluorouracil combined with epirubicin and oxaliplatin. J Cancer Res Clin Oncol 134: 929-936, 2008.
36. Cunningham D, Humblet Y, Siena S, et al: Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. NEngl J Med 351: 337-345, 2004.
37. Hurwitz HI, Fehrenbacher L, Hainsworth JD, et al: Bevacizumab in combination with fluorouracil and leucovorin: an active regimen for first-line metastatic colorectal cancer. J Clin Oncol 23: 3502-3508, 2005.
38. Shah MA, Ramanathan RK, Ilson DH, et al: Multicenter phase II study of irinotecan, cisplatin and bevacizumab in patients with metastatic gastric or gastroesophageal junction adenocarcinoma. J Clin Oncol 24: 5201-5206, 2005.
39. Pinto C, Di Fabio F, Siena S, et al: Phase II study of cetuximab in combination with FOLFIRI in patients with untreated advanced gastric or gastroesophageal junction adenocarcinoma (FOLCETUX study). Ann Oncol 18: 510-517, 2007.
40. Doi T, Koizumi W, Siena S, et al: Efficacy, tolerability and pharmacokinetics of gefitnib (ZD1839) in pretreated patients with metastatic gastric cancer. Proc Am Soc Clin Oncol 22: abs. 1036, 2003.
41. Dragovich T, McCoy S, Fenoglio-Preiser CM, et al: Phase II trial of erlotinib in gastroesophageal junction and gastric adenocarcinomas: SWOG0127. J Clin Oncol 24: 4922-4927, 2006.
42. Ling Y, Yang Y, Lu N, et al: Endostar, a novel recombinant human endostatin, exerts antiangiogenic effect via blocking VEGF-induced tyrosine phosphorylation of KDR/Flk-1 of endothelial cells. Biochem Biophys Res Commun 361: 79-84, 2007.
43. Jiang HQ, Li YL and Zou J: Effect of recombinant human endostatin on endometriosis in mice. Chin Med J (Engl) 120: 1241-1246, 2007.
44. Zhou ZW, Wan DS, Wang GQ, et al: Inhibitory effect of angiogenesis inhibitor YH-16 on liver metastases from colorectal cancer. Ai Zheng 25: 818-822, 2006.
45. Wang JW, Sun Y, Liu YY, et al: Results of randomized, multicenter, double-blind phase III trial of rh-endostatin (YH-16) in treatment of advanced non-small cell lung cancer patients. Chin J Lung Cancer 8: 283-290, 2005.
46. Lieto E, Ferraraccio F, Orditura M, et al: Expression of vascular endothelial growth factor (VEGF) and epidermal growth factor receptor (EGFR) is an independent prognostic indicator of worse outcome in gastric cancer patients. Ann Surg Oncol 15: 69-79, 2008.
47. Lievre A, Bachet JB, Le Corre D, et al: KRASmutation status is predictive of response to cetuximab therapy in colorectal cancer. Cancer Res 66: 3992-3995, 2006.
48. Lievre A, Bachet JB, Boige V, et al: KRASmutations as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab. J Clin Oncol 26: 374-379, 2008.
49. Blanke CD, Joensuu H, Demetri GD, et al: Outcome of advanced gastrointestinal stromal tumor (GIST) patients treated with imatinib mesylate: Four-year follow-up of a phase II randomized trial. Proc Am Soc Clin Oncol 24: abs. 7, 2006.
50. Innocenti F, Undevia SD, Iyer L, et al: Genetic variants in the UDP-glucuronosyltransferase 1A1 gene predict the risk of severe neutropenia of irinotecan. J Clin Oncol 22: 1382-1388, 2004.